Article

Tear formulations unique in dry eye therapy, management

Author(s):

Blink GelTears and Blink Tears Preservative-Free (Advanced Medical Optics) are two new over-the-counter products for the treatment of dry eye disease. These products are gaining in popularity with ophthalmologist because of the rapid long-lasting beneficial response they produce in this patient population and the absence of a preservative. The products are also beneficial for patients who have undergone LASIK and cataract surgery and develop subsequent dry eye signs and symptoms postoperatively.

Key Points

In addition to dry eye, the products also are beneficial for patients who have undergone LASIK and cataract surgery and develop subsequent dry eye signs and symptoms postoperatively, said Dr. Donnenfeld, founding partner of Ophthalmic Consultants of Long Island, Rockville Centre, NY, and Connecticut, and clinical professor of ophthalmology, New York University Medical Center, New York.

He and his colleagues have used these products for more than a year because of involvement in the original FDA clinical trials. Dr. Donnenfeld described the products as unique because of their different mechanism of action.

In addition, he said that he is "very impressed with the ability of the tears to maintain a normal ocular surface, to improve the patients' quality of vision by smoothing out the higher-order aberrations, and to provide relief from dry eye signs and symptoms. We found that because of the viscoelastic capabilities, [the new tears] adhere to the ocular surface and provide long-term relief of dry eye symptoms."

Preservative-free drop

In his practice, Dr. Donnenfeld said, he uses the preservative-free drop to treat all forms of dry eye, but he finds it particularly helpful for treating patients who develop dry eye symptoms after undergoing LASIK and cataract surgery when patients expect excellent quality of vision.

"In addition to smoothly coating the ocular surface, the tear formulation does this in a way that does not cause transient blurring of vision," he said. "With [the preservative-free drop], the patient benefits from the ease and comfort of a less viscous tear and the improved quality of vision, but there are no transient visual problems or gummy vision that might develop with some thicker tear formulations that tend to disrupt the normal tear film."

Another major advantage of these tears is the absence of a preservative, especially for patients who instill drops more often than four times a day, he said.

Gel drop

The gel drop is a thicker, more viscous tear that provides patients with more prolonged periods of relief from dry eye symptoms. Interestingly, Dr. Donnenfeld said, this product does not cause as much visual distortion as other viscous gel tear formulations.

"[The gel drop] stays in the tear film for longer than any of the other gel tears and because of that characteristic, it really provides prolonged comfort and relief of dry eye symptoms," he said. The drop contains a preservative (OcuPure, AMO), but this dissipates within several seconds upon instillation in the eye.

Dr. Donnenfeld and his colleagues use these tears with most patients with dry eye and prophylactically after cataract and LASIK procedures.

"We don't use tears enough in patients who have undergone surgery," he said. "Most patients who undergo these surgeries have a relative denervation of the cornea, which may prevent them from feeling the sensation of dry eye. Nevertheless, these patients are symptomatic and the tears certainly improve their quality of vision. This is an ideal tear for anyone who complains of fluctuations in vision. The tears give them that 'Wow!' effect of high-quality vision."

Dr. Donnenfeld said he also frequently uses these products in conjunction with loteprednol etabonate (Lotemax, Bausch & Lomb) and cyclosporine (Restasis, Allergan) to improve the immune component.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.